Blue light flexible cystoscopy (D-Light C PDD Flexible Videoscope System) with intravesical hexaminolevulinate HCl (HAL [Cysview]) for surveillance in the office setting significantly improved the detection of recurrent bladder tumors compared with white light cystoscopy.
"Overall, the take-home message is that [blue light cystoscopy], whether in the clinic or the OR, increases the detection of tumors," writes Jeffrey M. Holzbeierlein, MD.
“rAd-IFNα gene therapy is a breakthrough opportunity for effective local management of BCG-unresponsive NMIBC,” says researcher Colin P. N. Dinney, MD.
Photothermal treatment with epidermal growth factor receptor-directed gold nanorods results in considerable antineoplastic activity in an early study of bladder cancer.
Researchers from Wake Forest Baptist Comprehensive Cancer Center have made novel discoveries about the genomic signatures of cancers—including bladder cancer—in smokers and African-American patients.
New research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.
Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Evaluation of upper tract surveillance for high-grade, nonmuscle-invasive bladder cancer and evidence suggesting that androgen receptor activity may be related to recurrence and treatment of bladder cancer were among the take-home messages in this area from AUA 2017.
For suspected low-grade, newly diagnosed, or occasionally recurrent bladder cancer, a single post-transurethral resection of bladder tumor instillation of gemcitabine (Gemzar) reduces bladder cancer recurrence by 47%, according to a recent study.